Latest News
Provention’s success with T1D-delaying mAb will contend with the need to develop screening protocols
Provention’s success with T1D-delaying mAb will contend with the need to develop screening protocols
- April 01, 2021
Insulin Stimulates Production of Body Heat, New Study Finds
- March 22, 2021Source: MD alert
Teplizumab delays onset of type 1 diabetes in half of high-risk individuals
- March 15, 2021
SGLT2 inhibitors, or drugs used to treat type 2 diabetes, significantly reduce hospitalizations and mortality for diabetic patients with heart failure.
- March 15, 2021Source: Yale Daily News
Now that COVID-19 vaccines are being rolled out for adults in much of the world, pharmaceutical companies have started to conduct further trials to confirm whether the shots are also safe and effective for children and pregnant women.
- March 10, 2021
Inzucchi Wins 2021 Outstanding Physician-Clinician in Diabetes Award
- March 09, 2021
Diversity, Equity & Inclusion Update (March 2021)
- March 03, 2021Source: YaleNews
The drug, developed by biotechnology company Provention and evaluated by Yale researchers, has been awarded breakthrough status by the U.S. Food and Drug Administration and could be approved for general use by summer.
- March 01, 2021Source: M.D./alert
Nursing home residents at risk for overtreatment of diabetes